Report Sections

See All Reports

  • HP:0012056: Cutaneous melanoma
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0012056: Cutaneous melanoma

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (4)


    Name (Synonyms) Correlation
    drug150 Active control:Healthy Living Wiki 0.58
    drug2933 SSE educational intervention Wiki 0.58
    drug1445 Home sample collection of concerning mole with physician supervision Wiki 0.58
    Name (Synonyms) Correlation
    drug3219 Survey Administration Wiki 0.29

    Correlated MeSH Terms (2)


    Name (Synonyms) Correlation
    D008545 Melanoma NIH 1.00
    D008175 Lung Neoplasms NIH 0.24

    Correlated HPO Terms (1)


    Name (Synonyms) Correlation
    HP:0100526 Neoplasm of the lung HPO 0.24

    Clinical Trials

    Navigate: Correlations   HPO

    There are 3 clinical trials


    1 Observational Retrospective Register of Spanish Lung and Melanoma Cancer Patients With COVID19 Disease

    This is a multi-centre study on lung cancer patients which experienced COVID-19. Information on clinical features, clinical course, management and outcomes will be collected for both, thoracic cancers and COVID-19 infection. Firstly, investigators will be registered in an online secure registry. After that, a protocol will be developed in order to collect clinical data for the research. It will also include I on the care organization or the perception of the patient and their family members. The final stage will consist on retrospective data collection from patients. So, it is a retrospective study data collection, preceded by prospective data registry.

    NCT04344002
    Conditions
    1. Covid-19
    2. Lung Cancer
    MeSH:Lung Neoplasms Melanoma
    HPO:Cutaneous melanoma Melanoma Neoplasm of the lung

    Primary Outcomes

    Description: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as clinical data.

    Measure: Clinical data of lung cancer patients with COVID-19 diagnoses

    Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years

    Description: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as data about diagnosis

    Measure: Diagnosis data

    Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years

    Description: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as treatments received

    Measure: Treatments received

    Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years

    Description: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as prognostic factors.

    Measure: Prognostic factors

    Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years
    2 Targeted Melanoma Detection With Skin Self-examination: Leveraging the Mammogram Encounter

    The purpose of this study is to reduce melanoma mortality by improving early detection of melanoma with skin self-examination (SSE) among people who self-identify as being at risk and seek care for a concerning mole. Because women are more likely than men to perform SSE, women who are engaged in health promotion by having a recent screening mammogram are the focus of this research. Self-management of melanoma detection with SSE depends on ready access to dermatologists when a concerning mole is detected. In March 2020, the Illinois stay at home order (COVID-19) prohibited non-essential health care, including screening mammography and dermatology office-based care, and both are expected to remain limited until fall 2020. This submission explores a) the effectiveness of targeted melanoma detection (TMD) among women, who identify their risk of having a melanoma, learn to perform SSE, and perform SSE, and b) the effectiveness of adhesive patch-based home sample collection for genomic analysis to rule out melanoma in moles identified by women as concerning.

    NCT04420273
    Conditions
    1. Melanoma
    Interventions
    1. Behavioral: SSE educational intervention
    2. Other: Home sample collection of concerning mole with physician supervision
    3. Behavioral: Active control:Healthy Living
    MeSH:Melanoma
    HPO:Cutaneous melanoma Melanoma

    Primary Outcomes

    Description: Self-reported performance of SSE, a custom scale with the frequency and extent of SSE is completed in an online monthly survey

    Measure: Change in SSE performance

    Time: 90 days

    Description: Self-reported identification of concerning mole identified by user assigning scores to the border,color and diameter of the mole. A validated scoring system is used to categorize the border, color and diameter as 1 if normal, 2 if not sure, and 3 if abnormal.The sum of the scores indicates if the mole is concerning (sum of 3= benign, stop checking the mole; sum of 4- 7 monitor the mole for change in the next month; sum of 8-9 = concerning mole make an appointment to see a physician.

    Measure: Identification of concerning mole

    Time: 90 days

    Description: The quantity of cells obtained for genomic analysis will be assessed. The results of the genomic analysis will be validated with the pathological findings of the biopsied concerning mole. A Student t test will be performed for the null hypothesis of no difference between the genomic analysis and the pathological finding of melanoma.

    Measure: Effectiveness of adhesive patch-based home sample collection for genomic analysis of concerning moles to rule-out melanoma

    Time: 90 Days

    Secondary Outcomes

    Description: Self-reported responses to 7 items, each with a 5-point Likert scale (range 7-35) higher score= more anxiety

    Measure: Change in skin self-examination anxiety

    Time: 90 days

    Description: Self-reported responses to 7 items, each with a 5-point Likert scale (range 7-35) higher score = greater confidence.

    Measure: Change in confidence performing mole checks

    Time: 90 days

    Description: Electronic medical record review

    Measure: Number of physician visits for concerning moles

    Time: 5 months

    Description: Electronic medical record review

    Measure: Number of biopsies of concerning moles

    Time: 5 months
    3 Well-Being and Quality of Life in Melanoma Patients During COVID-19 Pandemic

    The primary purpose of this study is to gain an understanding of how experiences during the COVID-19 pandemic, regardless of COVID-19 status, may have impacted multiple domains of health-related quality of life and other areas such as COVID-19 specific psychological distress, and disruptions to health care, finances and social interactions. We will also evaluate the extent to which resiliency factors such as social support, perceived benefits under times of stress, and ability to manage stress may buffer associations between COVID-19 experiences and HRQoL. To meet these objectives, we have developed a 10-minute questionnaire that taps into these areas and is based on prior work addressing concerns of other pandemics or national crises. Participants will have previously consented to protocol PA15-0336 and have provided prior lifestyle data. This will allow us to connect the COVID-19 survey data with prior existing data.

    NCT04474301
    Conditions
    1. COVID-19 Infection
    2. Melanoma
    Interventions
    1. Other: Survey Administration
    MeSH:Melanoma
    HPO:Cutaneous melanoma Melanoma

    Primary Outcomes

    Description: Including exposure, risk factors, testing, isolation, seropositivity, hospitalization, or loss of family or friends.

    Measure: Experiences during the COVID-19 pandemic

    Time: Survey completion Up to 2 months

    Measure: COVID-19-specific psychological distress

    Time: Survey completion Up to 2 months

    Measure: COVID-19-specific health

    Time: Survey completion Up to 2 months

    Measure: COVID-19-specific financial and social disruptions

    Time: Survey completion Up to 2 months

    Measure: COVID-19-specific perceived benefits and social support

    Time: Survey completion Up to 2 months

    Measure: COVID-19-specific health related quality of life (HRQoL)

    Time: Survey completion Up to 2 months

    Description: Will evaluate the extent to which resiliency factors such as social support and perceived benefits moderate the effects of COVID-19 experiences on COVID-19-specific psychological distress and HRQoL.

    Measure: Effects of COVID-19 experiences on COVID-19-specific psychological distress and HRQoL

    Time: Survey completion Up to 2 months

    Description: Will explore the association between prior lifestyle data collected as part of PA15-0336 and COVID-19-specific psychological distress and HRQoL.

    Measure: Prior lifestyle data

    Time: Survey completion Up to 2 months

    HPO Nodes


    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook